Planep治疗效果怎么样？

Eplerenone (Planep) is a new type of selective aldosterone receptor antagonist that was approved for clinical use by the US Food and Drug Administration in 2002. Eplerenone (Planep) can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for congestive heart failure after acute myocardial infarction. Eplerenone (Planep) can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension.  

Eplerenone (Planep) is a selective aldosterone receptor antagonist that only acts on mineralocorticoid receptors but not on androgen and progesterone receptors. Eplerenone (Planep) treats patients with stage 1 and 2 hypertension with similar efficacy and reduction in systolic and diastolic blood pressure as enalapril. Eplerenone (Planep) also has a good antihypertensive effect in patients with essential hypertension with low renin levels who do not respond well to angiotensin-converting enzyme inhibitors and angiotensin receptor inhibitors. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone (Planep) can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.  

In a study of systolic hypertension in the elderly, 269 patients were treated with eplerenone (Planep) daily (50-200) mg and amlodipine (2.5-10) mg daily. The results showed that both drugs had the same effect in lowering systolic blood pressure, while amlodipine lowered diastolic blood pressure more significantly. In terms of target organ protection, both drugs improved carotid-femoral and carotid-radial pulse rates after 24 weeks of treatment. In terms of the incidence of adverse reactions, 19.9% ​​of the amlodipine group developed peripheral edema, while only 2.7% of the eplerenone (Planep) group developed hyperkalemia; 0.4% of the amlodipine group developed hyperkalemia, and 0.9% of the eplerenone (Planep) group developed hyperkalemia.